2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Cancer of Esophagus in 17 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Barrett's adenocarcinoma cell line, SEG-1, was exposed to the conjugated bile salt, glycochenodeoxycholic acid (GCDA)." | 3.72 | Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line. ( Anthony, T; Jaiswal, K; Lopez-Guzman, C; Nwariaku, F; Sarosi, GA; Tello, V, 2004) |
| "The expression level of miR-2053 in esophageal cancer cell lines was detected." | 1.62 | MicroRNA-2053 involves in the progression of esophageal cancer by targeting KIF3C. ( Jia, X; Li, S; Wei, L; Xu, L; Yao, W, 2021) |
| "The esophageal squamous cell carcinoma (ESCC) subtype with STMN1 overexpression has a high likelihood of lymphatic metastatic recurrence." | 1.48 | STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway. ( Huang, S; Jiang, W; Song, L; Wang, Z, 2018) |
| "Esophageal cancer is the sixth most common cause of cancer-related deaths worldwide." | 1.40 | Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. ( Cheung, AL; Guan, XY; Law, S; Li, B; Li, J; Qin, YR; Tsao, SW; Xu, WW; Zhang, LY, 2014) |
| "Necrosis was significantly reduced (P < 0." | 1.33 | MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro. ( Cunningham, C; Frankenberry, K; Jackson, BJ; McFadden, DW; Riggs, DR; Szwerc, MF; Vona-Davis, L, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, W | 1 |
| Jia, X | 1 |
| Xu, L | 1 |
| Li, S | 1 |
| Wei, L | 1 |
| Zhang, X | 3 |
| Cai, L | 1 |
| He, J | 1 |
| Li, X | 2 |
| Li, L | 1 |
| Chen, X | 2 |
| Lan, P | 1 |
| Jiang, W | 1 |
| Huang, S | 1 |
| Song, L | 1 |
| Wang, Z | 1 |
| Tao, H | 1 |
| Qian, P | 1 |
| Lu, J | 1 |
| Guo, Y | 1 |
| Zhu, H | 1 |
| Wang, F | 1 |
| Lu, H | 1 |
| Jiang, T | 1 |
| Ren, K | 1 |
| Li, ZL | 1 |
| Ren, J | 1 |
| Wu, G | 1 |
| Han, X | 1 |
| Gen, Y | 1 |
| Yasui, K | 1 |
| Nishikawa, T | 1 |
| Yoshikawa, T | 1 |
| Li, B | 2 |
| Li, J | 1 |
| Xu, WW | 1 |
| Guan, XY | 1 |
| Qin, YR | 1 |
| Zhang, LY | 1 |
| Law, S | 1 |
| Tsao, SW | 2 |
| Cheung, AL | 2 |
| Xi, R | 1 |
| Pan, S | 1 |
| Hui, B | 1 |
| Zhang, L | 1 |
| Fu, S | 1 |
| Gong, T | 1 |
| Guo, J | 1 |
| Che, S | 1 |
| Li, H | 1 |
| Gao, Q | 1 |
| Guo, L | 1 |
| Lu, SH | 1 |
| Zare, M | 1 |
| Jazii, FR | 1 |
| Soheili, ZS | 1 |
| Moghanibashi, MM | 1 |
| Ou, Y | 1 |
| Ma, L | 2 |
| Huang, Z | 1 |
| Zhou, W | 1 |
| Zhao, C | 1 |
| Zhang, B | 1 |
| Song, Y | 1 |
| Yu, C | 1 |
| Zhan, Q | 1 |
| Nguyen, DM | 1 |
| Chen, GA | 1 |
| Reddy, R | 1 |
| Tsai, W | 1 |
| Schrump, WD | 1 |
| Cole, G | 1 |
| Schrump, DS | 1 |
| Jaiswal, K | 1 |
| Tello, V | 1 |
| Lopez-Guzman, C | 1 |
| Nwariaku, F | 1 |
| Anthony, T | 1 |
| Sarosi, GA | 1 |
| Vona-Davis, L | 1 |
| Frankenberry, K | 1 |
| Cunningham, C | 1 |
| Riggs, DR | 1 |
| Jackson, BJ | 1 |
| Szwerc, MF | 1 |
| McFadden, DW | 1 |
| Cheung, PY | 1 |
| Wang, X | 1 |
| Ling, MT | 1 |
| Wong, YC | 1 |
| Mori, R | 1 |
| Ishiguro, H | 1 |
| Kimura, M | 1 |
| Mitsui, A | 1 |
| Sasaki, H | 1 |
| Tomoda, K | 1 |
| Mori, Y | 1 |
| Ogawa, R | 1 |
| Katada, T | 1 |
| Kawano, O | 1 |
| Harada, K | 1 |
| Fujii, Y | 1 |
| Kuwabara, Y | 1 |
| Okano, J | 1 |
| Gaslightwala, I | 1 |
| Birnbaum, MJ | 1 |
| Rustgi, AK | 1 |
| Nakagawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)[NCT05660083] | Phase 2 | 36 participants (Anticipated) | Interventional | 2023-01-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Cancer of Esophagus
| Article | Year |
|---|---|
MicroRNA-2053 involves in the progression of esophageal cancer by targeting KIF3C.
Topics: Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Disease P | 2021 |
Influence and mechanism of 5-aminolevulinic acid-photodynamic therapy on the metastasis of esophageal carcinoma.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Chromones; Down-Regulation | 2017 |
STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Chromones; Esophageal Neoplasms; Esophageal Squamous Cel | 2018 |
Autophagy inhibition enhances radiosensitivity of Eca‑109 cells via the mitochondrial apoptosis pathway.
Topics: Adenine; Animals; Autophagy; Cell Line, Tumor; Chromones; Esophageal Neoplasms; Gene Regulatory Netw | 2018 |
RUNX2 Plays An Oncogenic Role in Esophageal Carcinoma by Activating the PI3K/AKT and ERK Signaling Pathways.
Topics: Animals; Butadienes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Core Binding Fa | 2018 |
SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; E | 2013 |
Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway.
Topics: Androstadienes; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance | 2014 |
HPV16 E6-E7 induces cancer stem-like cells phenotypes in esophageal squamous cell carcinoma through the activation of PI3K/Akt signaling pathway in vitro and in vivo.
Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Survival; Chromones; Enzyme Activ | 2016 |
The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Proliferati | 2011 |
Downregulation of tropomyosin-1 in squamous cell carcinoma of esophagus, the role of Ras signaling and methylation.
Topics: Carcinoma, Squamous Cell; Cell Movement; Chromones; Down-Regulation; Enzyme Inhibitors; Esophageal N | 2012 |
Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Cell Surviva | 2013 |
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chromon | 2004 |
Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line.
Topics: Adenocarcinoma; Apoptosis; Barrett Esophagus; Caspases; Cell Division; Cell Line, Tumor; Chromones; | 2004 |
MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro.
Topics: Adenocarcinoma; Apoptosis; Barrett Esophagus; Butadienes; Cell Division; Cell Line, Tumor; Cell Surv | 2005 |
Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells.
Topics: Cell Line, Tumor; Cell Survival; Chromones; Enzyme Activation; Enzyme Inhibitors; Esophageal Neoplas | 2007 |
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tu | 2008 |
Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation.
Topics: Androstadienes; Blotting, Southern; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; | 2000 |